A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

February 1, 2022

Study Completion Date

February 24, 2022

Conditions

Norovirus Infections

Interventions

BIOLOGICAL

VXA-G1.1-NN

Norovirus GI.1 Norwalk VP1 Vaccine (VXA-G1.1-NN) E1/E3-Deleted Replication-Defective Recombinant Adenovirus 5 with Adjuvant Oral Tablet Vaccine.

Trial Locations (1)

AltaSciences LA, Cypress